Lecturer on Medicine, Beth Israel Deaconess Medical Center

Hematology

Daniel Deykin works in the field of Hematology. He went to medical school at Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Daniel Deykin is a published doctor as well. He has 99 publications published. The latest was: Cooperative studies in health services research in the Department of Veterans Affairs.

Publications

---

• Bleeding from aspirin prophylaxis of coronary disease.
• THE AGGREGATION OF HUMAN PLATELETS BY BACTERIAL ENDOTOXIN.
• THE FORMATION OF CHOLESTEROL ESTERS WITH RAT LIVER ENZYMES.
• RELEASE OF FREE FATTY ACIDS BY ADIPOSE TISSUE FROM RATS TREATED WITH TRIIODOTHYRONINE OR PROPYLTHIOURACIL.
• ACTIVATION PRODUCT, FACTOR IX, SERUM THROMBOTIC ACCELERATOR ACTIVITY, AND SERUM-INDUCED THROMBOSIS.
• The hydrolysis of long-chain fatty acid esters of cholesterol with rat liver enzymes.
• Fatty acid ethyl ester formation during ethanol metabolism in vivo.
• The esterification of cholesterol by rat liver particles.
• Serum thrombotic accelerator (STA) activity: its relation to the first phase of clotting.
• Evidence for an antithrombotic effect of Dicumarol.
• Theory and practice in acute venous thrombosis; a reappraisal.
• Managing oral anticoagulant therapy.
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
• Cooperative studies in health services research in the Department of Veterans Affairs.
• A state-of-the-art conference on databases pertaining to veterans' health. A resource for research and decision making.
• A clinical study monitoring low-intensity anticoagulant therapy with a standard-sensitivity thromboplastin.
• Porcine aortic endothelial cell membranes contain a LPAF: CoA-independent transacylase.
• Characterization of phospholipase A2 secretion from human platelets.
• Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials.
• Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy.
• Use of antiplatelet agents and anticoagulants in post-myocardial infarction.
• Mechanisms of hemostasis and arterial thrombosis.
• Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis.
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.
• Heparin induced thrombocytopenia: a prospective study.
• The A alpha chain composition of low solubility fibrinogen.
• The Ponte Vedra syndrome--an unexpected interaction between alcohol and aspirin.
• Autoimmune thrombocytopenic purpura-like syndrome in a patient with head and neck cancer.
• The risks and benefits of heparin therapy.
• Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. Enhanced activation of platelet phospholipase(s) for liberation of arachido...
• Current status of anticoagulant therapy.
• Ethanol potentiation of aspirin-induced prolongation of the bleeding time.
• Heparin-induced thrombocytopenia and recurrent thromboembolism.
• Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia.
• Platelet size as a determinant of platelet function.
• Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
• Activation of phospholipases A2 and C in pig aortic endothelial cells synthesizing prostacyclin.
• Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.
• Cryoprecipitate shortens the bleeding time and reduces bleeding complications in patients with uremia.
• The activation of phosphatidylinositol-hydrolyzing phospholipase A2 during prostaglandin synthesis in transformed mouse BALB/3T3 cells.
• Treatment of the bleeding tendency in uremia with cryoprecipitate.
• Tranylcypromine and 15-hydroperoxyarachidonate affect arachidonic acid release in addition to inhibition of prostacyclin synthesis in calf aortic endothelial cells.
• Platelet size and age determine platelet function independently.
• Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine.
• Luminal release of prostacyclin and thromboxane A2 by arteries distal to small-caliber prosthetic grafts.
• Coenzyme A-mediated arachidonic acid transacylation in human platelets.
• Arachidonoyl transacylase in human platelets. Coenzyme A-independent transfer of arachidonate from phosphatidylcholine to lysoplasmenylethanolamine.
• Arachidonic acid metabolism by platelets of differing size.
• Favorable balance of prostacyclin and thromboxane A2 improves early patency of human in situ vein grafts.
• Uremic bleeding.
• Inactivation of prostacyclin (PGI2) by erythrocytes.
• Thrombogenesis.
• A previously undescribed hereditary clotting abnormality.
• The role of the liver in serum-induced hypercoagulability.
• Plasma co-factors in adenosine diphosphate-induced aggregation of human platelets.
• An hepatic inhibitor of activated clotting factor X (Stuart).
• Current concepts: the use of heparin.
• The incorporation of acetate and palmitate into lipids by human platelets.
• Hepatic removal of activated factor X by the perfused rabbit liver.
• Further studies on the "Dynia" clotting abnormality.
• Hepatitis after Konyne administration.
• The subcellular distribution of platelet lipids labeled by acetate-1-14C.
• The clinical challenge of disseminated intravascular coagulation.
• Warfarin revisited.
• A computer-based teaching program in hemostasis.
• Regulation of heparin therapy.
• The diagnosis and treatment of bleeding tendencies. A brief review.
• Warfarin therapy. 2.
• Warfarin therapy. 1.
• Local and systemic factors in the pathogenesis of thrombosis.
• Evidence for a structural requirement for the aggregation of platelets by collagen.
• Editorial: Factor VIII inhibitors.
• Altered lipid metabolism in human platelets after primary aggregation.
• The assessment of drug-dependent and isoimmune antiplatelet antibodies by the use of platelet aggregometry.
• Methods for the separation of platelets from plasma. A comparison of functional and morphological integrity.
• Emerging concepts of platelet function.
• Effect of epinephrine on platelet lipid metabolism.
• Platelet dysfunction in glycogen storage disease type I.
• A serum-induced defect in fibrin formation.
• Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.
• Cumulative antiplatelet effect of low-dose enteric coated aspirin.
• Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction.
• Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: effect of endothelial cell seeding vs. perioperative aspirin.
• Solubilization and properties of Ca2+-dependent human platelet phospholipase A2.
• Effects of insulin and prior exercise on prostaglandin release from perfused rat muscle. Evidence that prostaglandins do not mediate changes in glucose uptake.
• Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood.
• The natural history of endothelial structure and function in arterialized vein grafts.
• "Therapeutic range" for oral anticoagulant therapy.
• Stimulation of Ca2+-activated human platelet phospholipase A2 by diacylglycerol.
• Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2.
• Anticoagulants in acute myocardial infarction.
• Tantalus revisited--the search for the ideal anti-thrombotic dose of aspirin.
• Elevated glucose alters eicosanoid release from porcine aortic endothelial cells.
• Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.
• Altered arachidonic acid metabolism and platelet size in atopic subjects.
• Effect of chronic low dose aspirin on platelet and vascular eicosanoid metabolism in nonhuman primates (Macaca fascicularis).
• Ionophore-induced metabolism of phospholipids and eicosanoid production in porcine aortic endothelial cells: selective release of arachidonic acid from diacyl and ethe...

Schools

---

• Harvard Medical School

• Mass General Hospital

• Beth Israel Hospital Boston

Doctors Specialties

---

• Hematology

Accepted Insurances

---

Education

---

• Beth Israel Deaconess Medical Center
• Massachusetts General Hospital
• Harvard Medical School

Hospital

---

• Beth Israel Deaconess Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Daniel R. Jacobson, MD This Doctor is OpenDoctor Recommended.
	Dr. Gary E. Gilbert, MD
	Dr. Louis D. Fiore, MD This Doctor is OpenDoctor Recommended.
	Colleen A. Livingstone, NP
	Dr. Abraham Zimelman, MD This Doctor is OpenDoctor Recommended.
	Dr. Vassiliki A. Boosalis, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog